US20050267222A1 - Stabilized composition - Google Patents

Stabilized composition Download PDF

Info

Publication number
US20050267222A1
US20050267222A1 US10/531,915 US53191505A US2005267222A1 US 20050267222 A1 US20050267222 A1 US 20050267222A1 US 53191505 A US53191505 A US 53191505A US 2005267222 A1 US2005267222 A1 US 2005267222A1
Authority
US
United States
Prior art keywords
low
molecular weight
stabilizer
active substance
granules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/531,915
Other languages
English (en)
Inventor
Motokazu Iwata
Megumi Fujita
Hideo Kurita
Kenichiro Kiyoshima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Sumitomo Pharma Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co Ltd, Takeda Pharmaceutical Co Ltd filed Critical Dainippon Pharmaceutical Co Ltd
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED, DAINIPPON PHARMACEUTICAL CO., LTD. reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KIYOSHIMA, KENICHIRO, FUJITA, MEGUMI, IWATA, MOTOKAZU, KURITA, HIDEO
Publication of US20050267222A1 publication Critical patent/US20050267222A1/en
Assigned to DAINIPPON SUMITOMO PHARMA CO., LTD. reassignment DAINIPPON SUMITOMO PHARMA CO., LTD. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: DAINIPPON PHARMACEUTICAL CO., LTD.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US10/531,915 2002-10-22 2003-10-21 Stabilized composition Abandoned US20050267222A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002-307241 2002-10-22
JP2002307241 2002-10-22
JP2003-186591 2003-06-30
JP2003186591 2003-06-30
PCT/JP2003/013419 WO2004037293A1 (ja) 2002-10-22 2003-10-21 安定化組成物

Publications (1)

Publication Number Publication Date
US20050267222A1 true US20050267222A1 (en) 2005-12-01

Family

ID=32179077

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/531,915 Abandoned US20050267222A1 (en) 2002-10-22 2003-10-21 Stabilized composition

Country Status (6)

Country Link
US (1) US20050267222A1 (ja)
EP (1) EP1559433A4 (ja)
JP (1) JPWO2004037293A1 (ja)
AU (1) AU2003301654A1 (ja)
CA (1) CA2502825A1 (ja)
WO (1) WO2004037293A1 (ja)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275301A1 (en) * 2002-10-11 2006-12-07 Shuji Ozaki Cell death-inducing agent
US20070254027A1 (en) * 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070281327A1 (en) * 2003-12-12 2007-12-06 Kiyotaka Nakano Methods of Screening for Modified Antibodies With Agonistic Activities
US20070280951A1 (en) * 2003-12-12 2007-12-06 Naoki Kimura Cell Death Inducing Agents
US20080206229A1 (en) * 2003-12-12 2008-08-28 Koichiro Ono Modified Antibodies Recognizing Receptor Trimers or Higher Multimers
US20080274110A1 (en) * 2004-04-09 2008-11-06 Shuji Ozaki Cell Death-Inducing Agents
US20090022687A1 (en) * 2005-05-18 2009-01-22 Chugai Seiyaku Kabushiki Kaisha Novel Pharmaceuticals That Use Anti-HLA Antibodies
US20090074854A1 (en) * 2005-03-30 2009-03-19 Genpharm Inc. Combined-step process for pharmaceutical compositions
US20090117097A1 (en) * 2005-06-10 2009-05-07 Chugai Seiyaku Kabushiki Kaisha Stabilizer for Protein Preparation Comprising Meglumine and Use Thereof
US20090214535A1 (en) * 2005-06-10 2009-08-27 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical Compositions Containing sc(Fv)2
US20090297501A1 (en) * 2005-03-31 2009-12-03 Chugai Seiyaku Kabushiki Kaisha Structural Isomers of sc(Fv)2
US20100092461A1 (en) * 2007-03-12 2010-04-15 Chugai Seiyaku Kabushiki Kaisha Remedy For Chemotherapy-Resistant Cancer Containing HLA Class I-Recognizing Antibody as the Active Ingredient and Use of the Same
US20100150927A1 (en) * 2006-07-13 2010-06-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
US20110059488A1 (en) * 2003-12-12 2011-03-10 Chugai Seiyaku Kabushiki Kaisha Anti-MPL Antibodies
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US10098873B2 (en) 2006-04-21 2018-10-16 The Procter & Gamble Company Compositions and kits useful for treatment of respiratory illness
CN109444438A (zh) * 2018-10-25 2019-03-08 宁波瑞源生物科技有限公司 一种用于aptt检测试剂的稳定剂及aptt检测试剂
US10660966B2 (en) 2014-12-04 2020-05-26 Ge Healthcare Limited Method for removing acetaldehyde
CN116250538A (zh) * 2021-12-09 2023-06-13 沈阳中化农药化工研发有限公司 一种含稳定剂的杀虫组合物及制备方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1803447T1 (sl) * 2004-09-09 2010-01-29 Psicofarma S A De C V Farmacevtski sestavek za zadrĺ˝evano sproĺ äśanje hidralazina in njegova uporaba kot podrpora zdravljenju raka
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
JP4901592B2 (ja) * 2007-05-14 2012-03-21 東洋製薬化成株式会社 アルデヒド系消毒剤の有効濃度判定用固形剤型インディケータ
JP5452051B2 (ja) * 2009-03-27 2014-03-26 杏林製薬株式会社 イミダフェナシン含有口腔内崩壊錠
US20140005128A1 (en) 2010-08-11 2014-01-02 Forest Laboratories Holdings Limited Treatments of gastrointestinal disorders
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
JP5918895B1 (ja) * 2015-05-21 2016-05-18 富士カプセル株式会社 ナルフラフィン塩酸塩含有カプセル製剤

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130255A (en) * 1990-12-13 1992-07-14 Genentech, Inc. Process for preparing storage stable pharmaceuticals
US5192561A (en) * 1991-09-19 1993-03-09 Wm. Wrigley Jr. Company Aspartame stability in chewing gum using an acid gelatin system
US5348666A (en) * 1993-03-31 1994-09-20 Union Carbide Chemicals & Plastics Technology Corporation Method for stabilizing glutaraldehyde in aqueous systems
US5356636A (en) * 1991-12-14 1994-10-18 Basf Aktiengesellschaft Stable vitamin and/or carotenoid products in powder form, and the preparation thereof
US5620704A (en) * 1994-11-07 1997-04-15 Warner-Lambert Company Process for stabilizing gelatin products
US5726180A (en) * 1993-06-30 1998-03-10 Takeda Chemical Industries, Ltd. Stabilized solid pharmaceutical preparation and method of producing the same
US5874106A (en) * 1996-03-12 1999-02-23 Novartis Finance Corporation Filled gelatin capsules
US5977153A (en) * 1991-09-20 1999-11-02 Camiener; Gerald W. Solid aldehyde and antimicrobial compositions useful as fixatives, preservatives and embalming agents
US6190701B1 (en) * 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
US6255331B1 (en) * 1999-09-14 2001-07-03 Rohm And Haas Company Stable biocidal compositions
US6328995B1 (en) * 1999-09-24 2001-12-11 Basf Aktiengesellschaft Stable vitamin and/or carotenoid products in powder form and process for their production
US6540991B2 (en) * 2001-04-06 2003-04-01 3M Innovative Properties Company Stabilized active materials
US20030064074A1 (en) * 1999-11-12 2003-04-03 Chang Robert C. Recombinant gelatins in vaccines
US20030215515A1 (en) * 2002-04-11 2003-11-20 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
US20050031691A1 (en) * 2002-09-11 2005-02-10 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
US20050037084A1 (en) * 2000-03-31 2005-02-17 Hideaki Nomura Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847975A1 (de) * 1978-11-04 1980-05-14 Merck Patent Gmbh Verfahren zur bindung von freiem formaldehyd in pharmazeutischen und kosmetischen zubereitungen
JPS60161925A (ja) * 1984-02-02 1985-08-23 Sanwa Kagaku Kenkyusho:Kk 安定なカリジノゲナーゼ打錠製剤の製法
JPS60233011A (ja) * 1984-05-04 1985-11-19 Ajinomoto Co Inc パツプ剤
JPH0761955B2 (ja) * 1988-04-28 1995-07-05 国立予防衛生研究所長 凍結乾燥ａ型肝炎ワクチン
JP2790659B2 (ja) * 1989-06-30 1998-08-27 帝国臓器製薬株式会社 ゼラチンカプセル剤
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
JP3203108B2 (ja) * 1993-08-26 2001-08-27 協和メデックス株式会社 グルコース−６−リン酸デヒドロゲナーゼの安定化方法
JP3845876B2 (ja) * 1995-04-20 2006-11-15 アステラス製薬株式会社 ピラジン誘導体又はその塩を含有する安定な注射用組成物及びその製造方法
JP2001122790A (ja) * 1999-10-22 2001-05-08 Mikasa Seiyaku Co Ltd 安定な褥瘡・皮膚潰瘍および創傷治療用製剤
BR0016334A (pt) * 1999-12-16 2002-09-10 Lilly Co Eli Composições de polipeptìdeo com estabilidade aperfeiçoada
CA2424656C (en) * 2000-10-13 2010-03-23 Cambridge Biostability Ltd. Composition and method for stable injectable liquids
JP3535120B2 (ja) * 2001-08-20 2004-06-07 富士カプセル株式会社 軟カプセル剤

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130255A (en) * 1990-12-13 1992-07-14 Genentech, Inc. Process for preparing storage stable pharmaceuticals
US5192561A (en) * 1991-09-19 1993-03-09 Wm. Wrigley Jr. Company Aspartame stability in chewing gum using an acid gelatin system
US5977153A (en) * 1991-09-20 1999-11-02 Camiener; Gerald W. Solid aldehyde and antimicrobial compositions useful as fixatives, preservatives and embalming agents
US5356636A (en) * 1991-12-14 1994-10-18 Basf Aktiengesellschaft Stable vitamin and/or carotenoid products in powder form, and the preparation thereof
US5348666A (en) * 1993-03-31 1994-09-20 Union Carbide Chemicals & Plastics Technology Corporation Method for stabilizing glutaraldehyde in aqueous systems
US5726180A (en) * 1993-06-30 1998-03-10 Takeda Chemical Industries, Ltd. Stabilized solid pharmaceutical preparation and method of producing the same
US5620704A (en) * 1994-11-07 1997-04-15 Warner-Lambert Company Process for stabilizing gelatin products
US5874106A (en) * 1996-03-12 1999-02-23 Novartis Finance Corporation Filled gelatin capsules
US6190701B1 (en) * 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
US6255331B1 (en) * 1999-09-14 2001-07-03 Rohm And Haas Company Stable biocidal compositions
US6328995B1 (en) * 1999-09-24 2001-12-11 Basf Aktiengesellschaft Stable vitamin and/or carotenoid products in powder form and process for their production
US20030064074A1 (en) * 1999-11-12 2003-04-03 Chang Robert C. Recombinant gelatins in vaccines
US20050037084A1 (en) * 2000-03-31 2005-02-17 Hideaki Nomura Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability
US6540991B2 (en) * 2001-04-06 2003-04-01 3M Innovative Properties Company Stabilized active materials
US20030215515A1 (en) * 2002-04-11 2003-11-20 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
US20050031691A1 (en) * 2002-09-11 2005-02-10 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158385B2 (en) 2002-10-11 2012-04-17 Chugai Seiyaku Kabushiki Kaisha Cell death-inducing agent
US20060275301A1 (en) * 2002-10-11 2006-12-07 Shuji Ozaki Cell death-inducing agent
US7993642B2 (en) 2003-12-12 2011-08-09 Chugai Seiyaku Kabushiki Kaisha Anti-MPL antibodies
US20110059488A1 (en) * 2003-12-12 2011-03-10 Chugai Seiyaku Kabushiki Kaisha Anti-MPL Antibodies
US20070281327A1 (en) * 2003-12-12 2007-12-06 Kiyotaka Nakano Methods of Screening for Modified Antibodies With Agonistic Activities
US20070280951A1 (en) * 2003-12-12 2007-12-06 Naoki Kimura Cell Death Inducing Agents
US20080206229A1 (en) * 2003-12-12 2008-08-28 Koichiro Ono Modified Antibodies Recognizing Receptor Trimers or Higher Multimers
US8008073B2 (en) 2003-12-12 2011-08-30 Chugai Seiyaku Kabushiki Kaisha Anti-Mpl antibodies
US20080274110A1 (en) * 2004-04-09 2008-11-06 Shuji Ozaki Cell Death-Inducing Agents
US8216611B2 (en) * 2005-03-30 2012-07-10 Mylan Pharmaceuticals Ulc Combined-step process for pharmaceutical compositions
US20090074854A1 (en) * 2005-03-30 2009-03-19 Genpharm Inc. Combined-step process for pharmaceutical compositions
US20090297501A1 (en) * 2005-03-31 2009-12-03 Chugai Seiyaku Kabushiki Kaisha Structural Isomers of sc(Fv)2
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
US20090022687A1 (en) * 2005-05-18 2009-01-22 Chugai Seiyaku Kabushiki Kaisha Novel Pharmaceuticals That Use Anti-HLA Antibodies
US8945543B2 (en) 2005-06-10 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
US9241994B2 (en) 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
US9777066B2 (en) 2005-06-10 2017-10-03 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
US20090214535A1 (en) * 2005-06-10 2009-08-27 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical Compositions Containing sc(Fv)2
US20090117097A1 (en) * 2005-06-10 2009-05-07 Chugai Seiyaku Kabushiki Kaisha Stabilizer for Protein Preparation Comprising Meglumine and Use Thereof
US11083697B2 (en) 2006-04-21 2021-08-10 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US10772848B2 (en) 2006-04-21 2020-09-15 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US11491151B2 (en) 2006-04-21 2022-11-08 The Procter & Gamble Company Compositions and kits useful for treatment of respiratory illness
US11141415B2 (en) 2006-04-21 2021-10-12 The Procter & Gamble Company Compositions and kits useful for treatment of respiratory illness
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US10098873B2 (en) 2006-04-21 2018-10-16 The Procter & Gamble Company Compositions and kits useful for treatment of respiratory illness
US11077074B2 (en) 2006-04-21 2021-08-03 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US10688089B2 (en) 2006-04-21 2020-06-23 The Procter & Gamble Company Compositions and kits useful for treatment of respiratory illness
EP2012765B1 (en) 2006-04-28 2015-03-25 The Procter and Gamble Company Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness
US20070254027A1 (en) * 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20100150927A1 (en) * 2006-07-13 2010-06-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
US20100092461A1 (en) * 2007-03-12 2010-04-15 Chugai Seiyaku Kabushiki Kaisha Remedy For Chemotherapy-Resistant Cancer Containing HLA Class I-Recognizing Antibody as the Active Ingredient and Use of the Same
US10660966B2 (en) 2014-12-04 2020-05-26 Ge Healthcare Limited Method for removing acetaldehyde
US11389538B2 (en) 2014-12-04 2022-07-19 Ge Healthcare Limited Method for removing acetaldehyde
US11964020B2 (en) 2014-12-04 2024-04-23 Ge Healthcare Limited Method for removing acetaldehyde
CN109444438A (zh) * 2018-10-25 2019-03-08 宁波瑞源生物科技有限公司 一种用于aptt检测试剂的稳定剂及aptt检测试剂
CN116250538A (zh) * 2021-12-09 2023-06-13 沈阳中化农药化工研发有限公司 一种含稳定剂的杀虫组合物及制备方法

Also Published As

Publication number Publication date
EP1559433A4 (en) 2009-11-04
CA2502825A1 (en) 2004-05-06
EP1559433A1 (en) 2005-08-03
WO2004037293A1 (ja) 2004-05-06
JPWO2004037293A1 (ja) 2006-02-23
AU2003301654A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
US20050267222A1 (en) Stabilized composition
AU2010285740C1 (en) Quinoline derivative-containing pharmaceutical composition
EP2328601B1 (en) Linaclotide-containing formulations for oral administration
EP2939662A1 (en) Pharmaceutical composition with improved stability, containing temozolomide, and preparation method therefor
JP2012184267A (ja) 安定性の向上した固形製剤およびその製造方法
JP5506111B2 (ja) ミルナシプラン製剤
EP1891952B1 (en) Pharmaceutical composition of olmesartan medoxomil
WO2017006855A1 (ja) 安定な経口投与用医薬組成物
EA015682B1 (ru) Фармацевтическая композиция
JP2005314413A (ja) 経口投与用医薬組成物
CA2663941A1 (en) Stabilized solid forms and method for the production thereof
US10188737B2 (en) Stabilized pharmaceutical composition
JPWO2005099698A1 (ja) 安定化された４−アミノ−５−クロロ−Ｎ−［（１Ｒ，３ｒ，５Ｓ）−８−メチル−８−アザビシクロ［３．２．１］オクタ−３−イル］−２−［１−メチルブタ−２−インイルオキシ］ベンズアミド含有組成物
WO2010001930A1 (ja) 固形内服製剤
JP3995414B2 (ja) 安定な医薬組成物
EP2116231A1 (en) Granulate comprising escitalopram oxalate
US20100021393A1 (en) Pharmaceutical Compositions Comprising Effervescent Agents and Fenofibrate
JP2004527518A (ja) プラバスタチンの安定薬剤組成物
KR20050096915A (ko) 안정한 토피라메이트 제제
CA3030392A1 (en) Solid preparation having improved light stability
JP2005281178A (ja) パンテチン含有粒状物
WO2020111089A1 (ja) 医薬組成物
JP3646310B1 (ja) 経口投与用医薬組成物
KR102027912B1 (ko) 경구투여용 탐술로신 또는 이의 약제학적으로 허용되는 염을 포함하는 서방성 삼중정제
KR101306088B1 (ko) (ｒ)-(-)-２-[５-(４-플루오로페닐)-３-피리딜-메틸아미노메틸]크로만을 함유하는 고형 약제학적 조성물

Legal Events

Date Code Title Description
AS Assignment

Owner name: DAINIPPON PHARMACEUTICAL CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IWATA, MOTOKAZU;FUJITA, MEGUMI;KURITA, HIDEO;AND OTHERS;REEL/FRAME:016921/0024;SIGNING DATES FROM 20050401 TO 20050412

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IWATA, MOTOKAZU;FUJITA, MEGUMI;KURITA, HIDEO;AND OTHERS;REEL/FRAME:016921/0024;SIGNING DATES FROM 20050401 TO 20050412

AS Assignment

Owner name: DAINIPPON SUMITOMO PHARMA CO., LTD., JAPAN

Free format text: CHANGE OF NAME;ASSIGNOR:DAINIPPON PHARMACEUTICAL CO., LTD.;REEL/FRAME:017546/0720

Effective date: 20051001

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION